On a mission to offer an alternative to people with CF
We are developing a therapy of 3 CFTR modulators combined with a personalized diagnostic tool to preselect responders to our therapy in the lab. The compounds are currently in a Phase 2b clinical trial.
Around 45,000 diagnosed people with CF do not have access to a life-saving treatment
We will be able to offer our therapy as an alternative to existing therapies, focusing on the ones that do not currently have access to treatment, and those that do not benefit from existing treatment thereby enabling broad patient access.
We target 3 groups of people with CF
Rare mutations - they have no treatment available
Common mutations that suffer from side effects or do not respond to available treatments
Countries where current modulator therapies are not available
Fair TX is committed to fostering fair value and equal access to treatment, regardless of patients’ background, financial status, or geographic location by:
making innovative treatments accessible
providing a fair return for shareholders
sustaining the company so that it can continue its mission
The current model for rare disease drug development resulting in high treatment costs needs to be challenged. Our combination of a clinical-stage CFTR modulator therapy and companion diagnostic significantly de-risks clinical development and therefore the costs of therapies, acting as a showcase for other rare diseases.
Join us in our mission
Creating a win-win situation for all stakeholders, transforming treatment of CF.
Get in touch to find out what opportunities we have to join us in our mission.